Home/Pipeline/Trivalent Influenza Virus Subunit Vaccine

Trivalent Influenza Virus Subunit Vaccine

Seasonal Influenza Prevention

CommercialMarket Tender Wins (e.g., Shanxi)

Key Facts

Indication

Seasonal Influenza Prevention

Phase

Commercial

Status

Market Tender Wins (e.g., Shanxi)

Company

A Chinese vaccine developer advancing proprietary subunit and mRNA vaccines, with a lead quadrivalent influenza vaccine in late-stage trials.

Drug	Company	Phase	Status
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent	Hualan Biological Vaccine	Commercial	Marketed
Influenza mRNA Vaccine	Pfizer	Phase 3	Active
Cell Culture-Based Quadrivalent Influenza Vaccine	Hualan Biological Engineering	Phase III	Active
Quadrivalent Influenza Vaccine (QIV)	Hualan Biological Engineering	Marketed	Approved
Trivalent Influenza Vaccine (TIV)	Hualan Biological Engineering	Marketed	Approved
Quadrivalent Influenza Virus Subunit Vaccine (Adult)	AB & B Biotech	Phase 3	Awaiting NDA Approval
Quadrivalent Influenza Virus Subunit Vaccine (Pediatric)	AB & B Biotech	Phase 3	Awaiting NDA Approval